| Date | Title | Description |
| 17.01.2026 | Hellman & Friedman рассматривает продажу производителя медоборудования Cordis более чем за $9 млрд | По данным источников, около шести публичных компаний сектора медицинских устройств в настоящее время анализируют потенциальные заявки на приобретение Cordis.
Hellman & Friedman приобрела Cordis в 2021 году у компании Cardinal Health при... |
| 07.11.2023 |
Cordis has a new CEO | Cordis CEO Scott Drake [Photo courtesy of Cordis]About two months after former Spectranetics CEO Scott Drake became executive board chair at Cordis, he’s moved into the corner office at the cardiology and endovascular devices company.
Drake... |
| 27.10.2023 | CMS changes coverage policy for carotid stenting to make it more widely available
What is different about the new CMS coverage determination for carotid stenting?
Hospitals performing carotid stenti... | Dave Fornell | October 18, 2023 | Cardiovascular Business | Interventional Cardiology |
| 05.09.2023 |
Cordis names former Spectranetics CEO as executive chair | Scott Drake is the new executive chair of Cordis’ board of directors [Image courtesy of Cordis]Interventional vascular tech company Cordis today announced that board member Scott Drake will be the new executive chair of its board of directo... |
| 20.10.2022 | Cordis To Acquire MedAlliance, For Up To $1.135 Billion | MedAlliance to be Acquired by Cordis36
Cordis, a Miami, FL-based provider of a development and manufacturing of interventional cardiovascular and endovascular technologies, acquired Nyon, Switzerland-based medical technology company MedAlli... |
| 08.07.2022 | CORDIS NAMES BRYAN LOO PRESIDENT OF ASIA-PACIFIC REGION | Seasoned medical technology leader tapped to maximize momentum in APAC
MIAMI LAKES, Fla., July 8, 2022 /PRNewswire/ -- Cordis, a global leader in cardiovascular technologies, today announced that Bryan Loo will assume the role of President ... |
| 12.03.2021 | Cardinal Health Signs Definitive Agreement to Sell its Cordis Business to Hellman & Friedman | March 12th, 2021
DUBLIN, Ohio
Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assum... |
| 29.05.2015 | Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | Otsuka Pharmaceutical Co Ltd lost a lawsuit challenging the U.S. Food and Drug Administration’s decision allowing other companies to make generic versions of the it’s antipsychotic drug, Abilify. Because the FDA typically grants years of ex... |
| 10.09.2014 | Press Release: Cordis Corporation launches INCRAFT AAA stent graft system for treatment of abdominal aortic aneurysms | FREMONT, CA – Cordis Corporation announced today the launch of its INCRAFT AAA Stent Graft System (INCRAFT System), an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdomi... |
| 12.03.2013 | Cordis Acquires Flexible Stenting Solutions, a Biomark Capital Fund IV Portfolio Company | Agreement Expands Treatment Options for Advanced Peripheral Artery Disease |
| 28.06.2012 | Stent development company initiating clinical trial raises $8M | Svelte is conducting a 30-patient clinical trial of its drug-eluting stent in New Zealand, a favorite for cardiology trials because its country-wide approval process is quicker and easier from a regulatory perspective.
Pomeranz, a veteran o... |
| 16.12.2011 | Fischell stent development co. raises $17 million in series B round | Pomeranz said the New Providence, New Jersey company’s Acrobat stent is the first advancement in delivering stents into the body in the past 15 years.
“It eliminates over 50 percent of the steps in a stenting procedure as well as the stenti... |
| 07.09.2011 | AtriCure: Is now the time for a strategic acquirer to step up? | “We’re coming upon a time in which AtriCure’s strategic value will increase over the next 12 to 18 months,” said Matt Dolan, an analyst with Roth Capital Partners. “But you could make an argument that the company is an attractive acquisitio... |
| 11.08.2010 | SPARQLZ Shines as a Vision for Linked Data Made Easy | SPARQLZ is a stealth technology project aimed to provide a graphical user interface for everyday users to assemble, edit, share and mash-up modular, persistent, real-time searches across the web of Linked Data. It’s a side project by an ind... |
| 06.08.2010 | Cordis wins again on appeal in ‘heated’ fight over Cypher stents | Cordis does not use any heat to bond metal to polymer in its Cypher stents and that’s more than cool with a federal appeals court.
A three-judge panel for the U.S. Court of Appeals for the Federal Circuit (CAFC) this week affirmed a lower c... |
| 05.05.2010 | Cleveland Clinic comes clean on cardiologist | By Mary Vanac
The Cleveland Clinic admitted that a former staff physician and inventor, Dr. Jay Yadav, did not run afoul of the health system’s conflicts of interest policy, as it claimed in 2006 in declining to renew Yadav’s employment con... |
| 19.02.2010 | Johnson & Johnson appeals patent ruling | Johnson & Johnson (NYSE:JNJ) appealed a federal judge’s ruling that four of its Cordis Corp. subsidiary’s drug-eluting stent patents are invalid, the latest salvo in its long-running infringement battle with Boston Scientific Corp. (NYS... |
| 21.01.2010 | Federal judge: Four J&J patents invalid in infringement dispute with Boston Scientific | Boston Scientific Corp. (NYSE:BSX) won the latest round in its long-running patent war with Johnson & Johnson (NYSE:JNJ) when a federal judge declared invalid a quartet of J&J subsidiary Cordis Corp’s. patents for drug-eluting stent... |
| 29.11.2006 | Impedance Cardiology raises $5 million | Impedance Cardiology Systems Inc., a Menlo Park, Calif.-based biotech startup, has raised $5 million in Series B funding, according to a regulatory filing cited by PE Week. Backers include Versant Ventures and Starfish Ventures (Australia).... |
| - | AtriCure: Is now the time for a strategic acquirer to step up? | Medical device giants looking to boost their atrial fibrillation product portfolios would do well to take a long, hard look at cardiac device-maker AtriCure (NASDAQ:ATRC).
Things have been looking up recently for Cincinnati-area AtriCure, a... |
| - | Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | TOP STORIES
Johnson & Johnson (NYSE: JNJ) has accepted Cardinal Health‘s $2 billion offer to acquire vascular medical device producer, Cordis.
Teva reached a $1.2 billion settlement with the Federal Trade Commission over
claims that Cep... |
| - | Stent development company initiating clinical trial raises $8M | A stent development company founded by serial entrepreneurs Robert Fischell and his sons David and Tim, has brought in $8 million in new investment for its second generation stent for cardiac surgery, raising about $25 million in debt and e... |
| - | Fischell stent development co. raises $17 million in series B round | Svelte Medical Systems, a medical device company started by serial entrepreneurs Robert Fischell and his sons David and Tim, has raised $17 million in a series B Round of financing — just under half of its $37 million target to develop its ... |
